Life sciences company Neogen (NASDAQ:NEOG) will be announcing earnings results this Tuesday after market hours. Here’s what to expect.
Neogen beat analysts’ revenue expectations last quarter, reporting revenues of $225.3 million, flat year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.
Is Neogen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Neogen’s revenue to be flat year on year, improving from the 3.6% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Neogen has missed Wall Street’s revenue estimates multiple times over the last two years.
With Neogen being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unfold for healthcare equipment and supplies stocks. However, investors in the segment have had steady hands going into earnings, with share prices flat over the last month. Neogen is up 3.4% during the same time .
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.